Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer

6 Mar 2025

Abstract excerpt

PURPOSE: Antibody-drug conjugates (ADC) are a promising approach for the management of patients with non-small cell lung cancer (NSCLC). However, only a small subset of patients derive benefit from these therapies. EXPERIMENTAL DESIGN: We used quantitative immunofluorescence assays to measure the levels of four ADC target proteins (HER2, TROP2, HER3, and EGFR) in three NSCLC tissue microarray cohorts stratified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40047548
DOI: 10.1158/1078-0432.ccr-24-3347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung CancerPMID 40047548Read ↗

Trop-2 expression in non–small cell lung cancerSemantic proximity Read ↗

Validation and Prospective Testing of a High Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology SlidesSemantic proximity Read ↗

EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.Semantic proximity Read ↗

Prospective Assessment of a Quantitative Immunofluorescent Assay to Measure HER2 and TROP2 concentrations on a Single Tissue Biopsy SlideSemantic proximity Read ↗

ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes.Semantic proximity Read ↗

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read ↗

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity Read ↗

The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.Semantic proximity Read ↗

Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.Semantic proximity Read ↗

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastomaSemantic proximity Read ↗

Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.